Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Surgery
Published in: BMC Surgery 1/2021

Open Access 01-12-2021 | Ultrasound | Research

HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study

Authors: Bin Zhou, Ning He, Jiaze Hong, Tong Yang, Derry Minyao Ng, Xudong Gao, Kun Yan, Xiaoxiang Fan, Zhi Zheng, Ping Chen, Jianjun Zheng, Qi Zheng

Published in: BMC Surgery | Issue 1/2021

Login to get access

Abstract

Background

The purpose of this study was to explore the efficacy and safety of high intensity focused ultrasound (HIFU) in gastric cancer with liver metastasis (GCLM) patients who were contraindicated for either hepatectomy or radiofrequency ablation (RFA).

Methods

This is a prospective, observational study on GCLM patients with 1–3 liver metastases. The primary gastric lesions were thoroughly resected and any case that exhibited extra-hepatic metastasis was excluded. A 1:2:2 propensity score-matching analysis was performed using a logistic regression model on the HIFU group, best supportive care (BSC) group, and palliative chemotherapy (PC) group. The primary endpoints include progression-free survival (PFS) and overall survival (OS).

Results

Forty patients were finally included, there were 8 cases in HIFU group, 16 cases in BSC group, and 16 cases in PC group. The median follow-up time for the entire cohort was 10 months. The median PFS was 16.5 months in HIFU group, 2 months in BSC group, and 5 months in PC group. The median OS was 27.5 months in the HIFU group, 7 months in the BSC group, and 11.5 months in the PC group. Additionally, no grade 3 or higher adverse events occurred in the HIFU group.

Conclusion

The results of this study showed that HIFU treatment could improve the long-term prognosis of GCLM patients without a significant increase in the occurrence of adverse events. Compared with PC and BSC, HIFU is the preferred treatment option when GCLM patients without extra-hepatic metastasis are unable to undergo either surgery or RFA.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
2.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.PubMedCrossRef
3.
D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808–16.PubMedPubMedCentralCrossRef
4.
Li Z, Fan B, Shan F, Tang L, Bu Z, Wu A, et al. Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study. World J Surg Oncol. 2015;13:212.PubMedPubMedCentralCrossRef
5.
Yu P, Zhang Y. Treatment of synchronous liver metastases from gastric cancer: a single-center study. Cancer Manag Result. 2020;12:7905–11.CrossRef
6.
7.
Chen J, Tang Z, Dong X, Gao S, Fang H, Wu D, et al. Radiofrequency ablation for liver metastasis from gastric cancer. Eur J Surg Oncol. 2013;39(7):701–6.PubMedCrossRef
8.
Qiu JL, Deng MG, Li W, Zou RH, Li BK, Zheng Y, et al. Hepatic resection for synchronous hepatic metastasis from gastric cancer. Eur J Surg Oncol. 2013;39(7):694–700.PubMedCrossRef
9.
Tatsubayashi T, Tanizawa Y, Miki Y, Tokunaga M, Bando E, Kawamura T, et al. Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging. Gastric Cancer. 2017;20(2):387–93.PubMedCrossRef
10.
Guner A, Son T, Cho I, Kwon IG, An JY, Kim HI, et al. Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer. 2016;19(3):951–60.PubMedCrossRef
11.
Tang K, Zhang B, Dong L, Wang L, Tang Z. Radiofrequency ablation versus traditional liver resection and chemotherapy for liver metastases from gastric cancer. J Int Med Res. 2020;48(7):300060520940509.PubMedCrossRef
12.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.PubMedCrossRef
13.
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013.PubMedPubMedCentralCrossRef
14.
15.
Jin C, Zhu H, Wang Z, Wu F, Chen W, Li K, et al. High-intensity focused ultrasound combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: long-term follow-up and clinical analysis. Eur J Radiol. 2011;80(3):662–9.PubMedCrossRef
16.
Diana M, Schiraldi L, Liu YY, Memeo R, Mutter D, Pessaux P, et al. High intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and the digestive system-current state of the art and future perspectives. Hepatobil Surg Nutr. 2016;5(4):329–44.CrossRef
17.
Ji Y, Zhang Y, Zhu J, Zhu L, Zhu Y, Hu K, et al. Response of patients with locally advanced pancreatic adenocarcinoma to high-intensity focused ultrasound treatment: a single-center, prospective, case series in China. Cancer Manag Res. 2018;10:4439–46.PubMedPubMedCentralCrossRef
18.
Yang T, Ng DM, Du N, He N, Dai X, Chen P, et al. HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phase I clinical trial. Surg Endosc. 2020;8:654.
19.
Zhang L, Zhu H, Jin C, Zhou K, Li K, Su H, et al. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol. 2009;19(2):437–45.PubMedCrossRef
20.
Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012;67(5):1025–39.PubMedCrossRef
21.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.PubMedCrossRef
22.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef
23.
Gu L, Chen P, Su H, Li X, Zhu H, Wang X, et al. Clinical significance of tumor deposits in gastric cancer: a retrospective and propensity score-matched study at two institutions. J Gastrointest Surg. 2020;24(11):2482–90.PubMedCrossRef
24.
Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric cancer, Version 3.2016, NCCN clinical practice guidelines in oncology. JNCCN. 2016;14(10):1286–312.PubMed
25.
Mitachi Y, Sakata Y, Ohtsu A, Hyodo I, Katsu K, Sairenji M, et al. Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study. Gastric Cancer. 2002;5(3):160–7.PubMedCrossRef
26.
Kakeji Y, Morita M, Maehara Y. Strategies for treating liver metastasis from gastric cancer. Surg Today. 2010;40(4):287–94.PubMedCrossRef
27.
Toyokawa T, Ohira M, Sakurai K, Amano R, Kubo N, Tanaka H, et al. Long-term survival with complete remission after hepatic arterial infusion chemotherapy for liver metastasis from gastric cancer: a case report. World J Surg Oncol. 2015;13:268.PubMedPubMedCentralCrossRef
28.
Moriya A, Hyodo I, Nishina T, Imaoka H, Imagawa A, Doi T, et al. Extensive liver metastasis of gastric cancer effectively treated by hepatic arterial infusion of 5-fluorouracil/cisplatin. Gastric Cancer. 2000;3(2):110–5.PubMedCrossRef
29.
Vogl TJ, Gruber-Rouh T, Eichler K, Nour-Eldin NE, Trojan J, Zangos S, et al. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results. Eur J Radiol. 2013;82(2):258–63.PubMedCrossRef
30.
Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329–38.PubMedCrossRef
31.
Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197(6):728–36.PubMedCrossRef
32.
Zhang W, Yu Y, Fang Y, Wang Y, Cui Y, Shen K, et al. Systemic chemotherapy as a main strategy for liver metastases from gastric cancer. Clin Transl Oncol. 2015;17(11):888–94.PubMedCrossRef
33.
Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19(3):968–76.PubMedCrossRef
34.
Aliyev S, Agcaoglu O, Aksoy E, Taskin HE, Vogt D, Fung J, et al. Efficacy of laparoscopic radiofrequency ablation for the treatment of patients with small solitary colorectal liver metastasis. Surgery. 2013;154(3):556–62.PubMedCrossRef
35.
Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H, et al. High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience. Ann Surg. 2011;253(5):981–7.PubMedCrossRef
36.
Cheung TT, Poon RT, Jenkins CR, Chu FS, Chok KS, Chan AC, et al. Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas. Liver Int. 2014;34(6):e136-143.PubMedCrossRef
37.
Shirasu H, Tsushima T, Kawahira M, Kawai S, Kawakami T, Kito Y, et al. Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer. 2018;21(2):338–44.PubMedCrossRef
38.
Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–22.PubMedPubMedCentralCrossRef
39.
Imai K, Allard MA, Castro Benitez C, Vibert E, Sa Cunha A, Cherqui D, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg. 2017;104(5):570–9.PubMedCrossRef
40.
Picado O, Dygert L, Macedo FI, Franceschi D, Sleeman D, Livingstone AS, et al. The role of surgical resection for stage iv gastric cancer with synchronous hepatic metastasis. J Surg Res. 2018;232:422–9.PubMedCrossRef
41.
Li J, Xi H, Cui J, Zhang K, Gao Y, Liang W, et al. Minimally invasive surgery as a treatment option for gastric cancer with liver metastasis: a comparison with open surgery. Surg Endosc. 2018;32(3):1422–33.PubMedCrossRef
42.
Yagi Y, Seshimo A, Kameoka S. Prognostic factors in stage IV gastric cancer: univariate and multivariate analyses. Gastric Cancer. 2000;3(2):71–80.PubMedCrossRef
43.
Wu P, Wang P, Ma B, Yin S, Tan Y, Hou W, et al. Palliative gastrectomy plus chemotherapy versus chemotherapy alone for incurable advanced gastric cancer: a meta-analysis. Cancer Manag Res. 2018;10:4759–71.PubMedPubMedCentralCrossRef
44.
Wu AW, Yuan P, Li ZY, Tang L, Bu ZD, Ren H, et al. Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study. Fut Oncol. 2016;12(18):2107–16.CrossRef
45.
Maloney E, Hwang JH. Emerging HIFU applications in cancer therapy. Int J Hypertherm. 2015;31(3):302–9.CrossRef
46.
Cheng CS, Chen L, Xie J, Chen Z. Multimodality palliative treatment with transarterial chemoembolization and high-intensity focused ultrasound for gastric leiomyosarcoma multiple liver metastasis pain: A case report. Medicine. 2019;98(39):e17328.PubMedPubMedCentralCrossRef
47.
Park MY, Jung SE, Cho SH, Piao XH, Hahn ST, Han JY, et al. Preliminary experience using high intensity focused ultrasound for treating liver metastasis from colon and stomach cancer. Int J Hypertherm. 2009;25(3):180–8.CrossRef
48.
Sung HY, Cho SH, Kim JI, Cheung DY, Han JY, Kim JK, et al. High intensity focused ultrasound therapy resulted in a complete response in a patient with advanced gastric cancer with liver metastases: a case report. Eur J Gastroenterol Hepatol. 2008;20(7):707–9.PubMedCrossRef
49.
Ji Y, Zhu J, Zhu L, Zhu Y, Zhao H. High-intensity focused ultrasound ablation for unresectable primary and metastatic liver cancer: real-world research in a Chinese tertiary center with 275 cases. Front Oncol. 2020;10:519164.PubMedPubMedCentralCrossRef
Metadata
Title
HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study
Authors
Bin Zhou
Ning He
Jiaze Hong
Tong Yang
Derry Minyao Ng
Xudong Gao
Kun Yan
Xiaoxiang Fan
Zhi Zheng
Ping Chen
Jianjun Zheng
Qi Zheng
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Surgery / Issue 1/2021
Electronic ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-021-01307-y

Other articles of this Issue 1/2021

BMC Surgery 1/2021 Go to the issue

Research

Significance of postoperative adjuvant chemotherapy with an oxaliplatin-based regimen after simultaneous curative resection for colorectal cancer and synchronous colorectal liver metastasis: a propensity score matching analysis

Research article

A comparison of postoperative outcomes after open and laparoscopic reduction of Petersen's Hernia: a multicenter observational cohort study

Research

Sonographic and pathological features of metaplastic squamous cell carcinoma of the breast: a case series

Research article

Safe standard remnant liver volume after hepatectomy in HCC patients in different stages of hepatic fibrosis

Research article

The risk factors and care measures of surgical site infection after cesarean section in China: a retrospective analysis

Research

Comparing quality of life between patients undergoing trans-areola endoscopic thyroid surgery and trans-oral endoscopic thyroid surgery